S80017
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱 上海源葉生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/5/15 19:02:20
- 訪問次數(shù) 158
聯(lián)系方式：何小姐15921386130 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說明是化工儀器網(wǎng)上看到的信息，謝謝!
- 提示：詳情請(qǐng)下載說明書。
- 產(chǎn)品描述： Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
- 靶點(diǎn)： CK2α:1 nM (IC50);CK2α':1 nM (IC50)
- 體內(nèi)研究： Silmitasertib (CX-4945) (25 or 75 mg/kg, p.o.) is well tolerated and demonstrated robust antitumor activity with concomitant reductions of the mechanism-based biomarker phospho-p21 (T145) in murine xenograft models
- 參考文獻(xiàn)：
1. Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98. 2. Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7(2):1323-40. 3. Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.
- 溶解度： DMSO : ≥ 35 mg/mL (100.07 mM) 0.1 M NaOH : 33.33 mg/mL (95.29 mM; ultrasonic and adjust pH to 9 with NaOH)
- 保存條件： -20℃
- 配置溶液濃度參考：
1mg 5mg 10mg 1 mM 2.859 ml 14.295 ml 28.59 ml 5 mM 0.572 ml 2.859 ml 5.718 ml 10 mM 0.286 ml 1.43 ml 2.859 ml 50 mM 0.057 ml 0.286 ml 0.572 ml
- 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的性，僅供客戶參考交流研究之用。
采購中心
化工儀器網(wǎng)